This is a Euroscicon Small Conference, an outline of the day can be found at
Whilst biopharmaceuticals remain a major component of the global therapeutics market, the ever expanding portfolio of products losing patent protection and with increasing healthcare costs remaining a poignant issue, the opportunity for development of competing, follow on biologics remains an attractive proposition for both Biotech and Pharma companies alike. However, as these biosimilar markets are captured how we manage the life cycle of these products and target specific patient and commercial benefits to maximise our product development strategies becomes increasingly important.
This Euroscicon biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place.
This event has CPD accreditation
Specialists in regulatory strategy and affairs, Biopharmaceutical developers/manufacturers including analytics/characterisation, marketing professionals, product enabling technology development companies
Meeting Chair: Dave Simpson PhD, Director, Virodigm Ltd
This event is part of the 2013 Euroscicon BioTherapeutics Week,
to find out more see www.biotherapeutics2013.com
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chairs: Dave Simpson PhD, Director, Virodigm Ltd
10:00 – 10:30 Novel Substituable Glycans in Biobetter Development
Jenny Thirlway, Glythera
With multiple products facing the prospect of market erosion as they approach their patent cliffs, efforts have increased to capture markets through development of biosimilars or through further improvement to the originator into next generation products. Half-life extension using PEGylation or cell lines / strains developed to modulate naturally occurring N-linked glycans have enjoyed notable success however, the latter can often be difficult to control during scaled up production. More recent strategies have included the direct substitution of the natural glycan with a modified version resulting in a similar product profile to the originator, characterisable by the same methods.
10:30 – 11:00 Critical steps in the development of Biosimilars
Dr Robert E. Zoubek, Formycon AG, Germany
The proof of safety and efficacy of a Biosimilar is demonstrated by its comparability to the reference medicinal product in extensive biochemical and specially designed non-clinical and clinical studies. Therefore, Biosimilar development differs from the development of Novel Biopharmaceuticals and its requirements on the Chemistry and Manufacturing Control (CMC) exceed those of Novel pharmaceuticals.
11:00 – 11:30 Speakers’ photo then mid-morning break and trade show
11:30 – 12:00 Biosimilars: The Race to Market and Cost Mitigation
Adam Bentley, Eden Biodesign, UK
12:00 – 12:30 Rational design of biobetters
Manuel Carballo-Amador, Faculty of Life Sciences, University of Manchester, UK.
Protein design is a potent approach for improving protein physicochemical properties with potential consequences for stability, activity, and solubility of proteins. Protein solubility plays an important role for recombinant therapeutic proteins during protein expression, purification, long-term storage and drug administration. Based on protein structure, Chan and Warwicker developed an algorithm to predict protein solubility, defining polar and non-polar patches on the protein surface. Using this algorithm, we predicted amino acid changes that would facilitate expression of forms of human erythropoietin (HuEPO) of directed solubility in E. coli. We found that a single point mutation (changing a single amino acid from positive to negative charge) verified the predicted effect on HuEPO solubility (the distribution between soluble and inclusion body fractions) in three different E. coli strains (Bl21 (DE3), CodonPlus and SHuffle). Further application of this algorithm will provide a powerful tool for the design of biobetters, with enhanced solubility and stability.
12:30 – 13:30 Lunch and trade show
13:30 – 14:00 Enabling Less Frequent, Self-administration Blood Factors – Better for Haemophilia Patients
Dr Ji-won Choi, Polytherics¸UK
Blood factors such as FVIIa, FVIII and FIX are life-saving treatments for Haemophilia A, B and trauma patients with uncontrolled bleeding. Current treatments can only be given as IV infusion, which is costly and inconvenient for haemophilia sufferers. Improved "immune-silent" forms of FVIIa, FVIII and FIX have been developed using site-specific PEGylation. In preclinical studies, PEGylated blood factors showed extended haemostatic cover for reduced dosing frequency. PEGylation also enabled previously unachievable subcutaneous injection for self-administration at home.
14: 00 - 14:30 Regulatory & Clinical Development Considerations for Biosimilars
Gerry McGettigan, Kinesys Consulting Ltd
The idea is to provide background to the legislation and guidance, followed by discussion of some of the typical development challenges and decisions.
14: 30 - 15:00 Biosimilars: Clinical and Commercial Advantages Through The Application of Manufacturing Technologies
Mr John Mcguire, DSM¸UK
· Key considerations in the development of Biosimilars
· The application of technologies to Biosimilar development and manufacturing
· The competitive edge that technologies bring including CMC risk management and improved Cost of Goods
15:00– 15:30 Afternoon break and trade show
15:30 - 16:00 Molecular Characterization of Biotherapeutics: Possibilities and Practicalities
Eric Chang,Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, M13 9PT, UK.
The molecular characterization of protein therapeutics is very difficult due to the presence of a wide variety of post-translational modifications. Two of the main tools available for biopharmaceutical analytics are chromatography and mass spectrometry. In this presentation, we describe our work applying these approaches, especially with a view to the investigation of modifications such as phosphorylation, methylation, methionine oxidation, glycosylation and other charge variants.
16: 00 - 17:00 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day plus Afternoon Tea/Coffee and trade show
17:00 Chairman’s summing up
Keywords: biopharmaceutical, drug delivery, Biosimilar, Regulatory, CMC,EU, Product registration, Biosimilars, Biologicals, Regulatory, Monoclonal antibodies, process development, automation, cell line, bioreactor, Characterisation, Biosimilarity, Comparability,biobetters, next generation biologics, technologies,CMC, Biosimilar, Comparability, Similarity, CTD,Biobetter, enabling, technologies, glycan, characterization, chromatography, mass spectrometry, post-translational modifications, variants, PEGylation, FIX, FVIIa, FVIII, haemophilia
About the Chair
David’s background is in cell line, process and analytical development, Tech Transfer and manufacturing of clinical products. Formerly of Eden Biodesign, David led the process development capabilities and post-acquisition by Watson Pharmaceuticals led the development and manufacturing of a recombinant FSH biosimilar product. David now owns an independent consultancy supporting all aspects of biopharmaceutical product and commercial development needs.
About the Speakers
Gerry McGettigan, a molecular biologist, has twenty years' experience in the biotechnology and pharmaceutical industries, in regulatory affairs, clinical development and business development. He has worked with large and medium pharma companies (Almirall and Glaxo) and was Regulatory & Scientific Affairs Director of The Liposome Company, a US biotechnology firm.
He founded the European regulatory affairs and product development consultancy company, GMG BioBusiness Ltd, which was sold to a top 5 CRO in 2005. He also set up and was CEO of the Catalan biotechnology development agency, Biocat. Gerry has worked directly with many clients on projects ranging from early stage regulatory strategy and complex biotechnology products, to MAAs for novel healthcare products.
Gerry has excellent relationships with top level business, science and governmental executives. Gerry is a member of TRI Cap, a group of independent investors, through which he invests in biotech / pharma and other companies. Gerry is Non-Executive Director of two biotech companies, Syntropharma and Biopta.
Robert Zoubek is Director for Scientific Affairs at Formycon, a company which offers and performs Biosimilar development since 2003 (formerly as Scil Biopharma Services). As a passionate biochemist with more than 10 years of experience in protein chemistry, he squired numerous development projects thus knowing the needs in biosimilar development. Robert studied biology at the LMU Munich and business administration at the University of Manchester. He attained his PhD from the Medical School of Erlangen for his studies on therapeutic peptides. After the following postdoc fellowship he joined GlycoForm in Abingdon/ UK, where he developed platform technologies for Biobetters. Robert joined Formycon (former Scil Technology) in 2009. He supervised the analytical laboratories and implemented new sensitive methods for protein characterisation and comparability exercises.
Eric Chang is a PhD student in Biotechnology at the University of Manchester working with Prof Alan Dickson, Dr David Knight and Dr Kenneth Cook. He is sponsored by Dionex of Thermo Scientific. His work involves the characterisation of therapeutic proteins.
Having completed a biochemistry PhD at the University of Nottingham,
Jenny Thirlway began a Post Doc at the University of Manchester studying Calcium Dependent Antibiotics from S. coelicolor. Jenny then joined Eden Biodesign where she was responsible for the cell line / strain and fermentation development teams. Post-acquisition by Watson Pharmaceutical (now Actavis) she was involved in development, scale up and manufacture of an FSH biosimilar product. Jenny joined Glythera immediately after an investment of £2M to spin the company out from Bath University and now oversees the development of Glythera’s core technologies centred on stable linker and glycan chemistries.
Ji-won Choi joined the founding team in 2003 to establish and lead the biology department responsible for the in vitro and in vivo assessment of PEGylated and ADC-based therapeutics. He is also a co-inventor of several PolyTherics technologies. As Director of Scientific Evaluation, Ji-won is currently responsible for the evaluation of internal and external product and technology concepts. His role also covers grants, project management and steering. Ji-won awarded a PhD in Virology from Imperial College London, UK.
John McGuire studied as an undergraduate and post graduate at University of Strathclyde and has been a registered pharmacist since 1992. He has more than 15 years experience in various companies and roles in the biopharmaceutical industry. These roles have included analytical development, characterization and QC, as well as clinical and commercial manufacture of drug substance and drug product. John’s roles have encompassed a wide scope of products including recombinant, vaccines and traditional chemicals. John also has extensive project/program management experience across a number of areas, including pre-clinical, clinical and commercial projects. Furthermore, John has a keen interest in Biosimilar development and has direct experience in a previous role where he managed the CMC aspects of a number of programs. This experience has been gained within GW/GSK, WyethBiopharma, UCB and Lonza Biologics. John joined the Business Development group in DSM Biologics in May 12 and has responsibilities across a number of European territories.
Event Web Site: www.regonline.co.uk/biosimilar2013
Phone: 07507 799380
For accommodation and travel please contact firstname.lastname@example.org
For enquiries regarding payment email: email@example.com
You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process). After registration you will be emailed details of where to send your cheque.
Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly
Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration. After registration you will be emailed details of where transfer your money.
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"
EuroSciCon Ltd. Registered in England and Wales,
Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5